Loading clinical trials...

A Study of CIN-107 in Adults With Treatment-Resistant Hypertension (rHTN) | Clinical Trials | Clareo Health

COMPLETEDPHASE2

A Study of CIN-107 in Adults With Treatment-Resistant Hypertension (rHTN)

A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group, Dose-Ranging Study to Evaluate the Efficacy and Safety of Multiple Dose Strengths of CIN-107 as Compared to Placebo After 12 Weeks of Treatment in Patients With Treatment-Resistant Hypertension (rHTN)

NCT04519658•CinCor Pharma, Inc.

View on ClinicalTrials.gov

Summary

This is a randomized, double-blind, placebo-controlled, dose-ranging Phase 2 study to evaluate the efficacy and safety of CIN-107 as compared to placebo after 12 weeks of treatment in patients with treatment-resistant hypertension (rHTN).

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Is on a stable regimen of ≥ 3 antihypertensive agents (one of which is a diuretic) for at least 4 weeks prior to randomization;
•Be at least 70% compliant to their anti-hypertensive medication regimen;
•Has a seated BP ≥ 130/80 mmHg;
•Agrees to comply with the contraception and reproduction restrictions of the study; and
•Able to understand and willing to comply with all study visits, procedures, restrictions, and provide written informed consent according to institutional and regulatory guidelines.

Exclusion Criteria

•Has a seated SBP ≥ 180 mmHg or DBP ≥ 110 mmHg;
•Has a body mass index (BMI) \> 40 kg/m2;
•Has an upper arm circumference \< 7 or \> 17 inches;
•Has been on night shifts at any time during the 4 weeks before Screening;
•Is using a beta blocker for any primary indication other than systemic hypertension (eg, migraine headache);
•Is not willing or not able to discontinue an MRA or a potassium sparing diuretic as part of an existing antihypertensive regimen;
•Is not willing or not able to discontinue taking a potassium supplement;
•Has documented estimated glomerular filtration rate (eGFR) \< 45 mL/min/1.73m2
•Has known and documented New York Heart Association stage III or IV chronic heart failure
•Has had a stroke, transient ischemic attack, hypertensive encephalopathy, acute coronary syndrome, or hospitalization for heart failure within 6 months before Screening;
+9 more criteria

Locations (80)

CinCor Site 16

Birmingham, Alabama, United States

CinCor Site 38

Birmingham, Alabama, United States

CinCor Site 61

Saraland, Alabama, United States

CinCor Site 90

Tucson, Arizona, United States

CinCor Site 82

Anaheim, California, United States

CinCor Site 91

Granada Hills, California, United States

CinCor Site 25

Lincoln, California, United States

CinCor Site 73

Los Angeles, California, United States

CinCor Site 36

Los Angeles, California, United States

CinCor Site 34

Lynwood, California, United States

Key Dates

Start Date

October 12, 2020

Primary Completion Date

June 14, 2022

Completion Date

June 14, 2022

Last Updated

July 24, 2023

Enrollment

275

ACTUAL participants

Conditions

Resistant Hypertension

Interventions

CIN-107

DRUG

Placebo

DRUG

Endothelin-1 Receptor Blockade in Resistant Hypertension

NCT04388124

Resistant Hypertension

View study

RECRUITING

Symplicity China Study

NCT07081243

Resistant Hypertension

View study

RECRUITINGPHASE2

Endocalyx in Treatment Resistent Hypertension

NCT06940011

Treatment Resistant Hypertension

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 24, 2023Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Study of CIN-107 in Adults With Treatment-Resistant Hypertension (rHTN)

Inclusion Criteria

Exclusion Criteria

Endothelin-1 Receptor Blockade in Resistant Hypertension

Symplicity China Study

Endocalyx in Treatment Resistent Hypertension

Evaluation of Two Isometric Exercises in the Reduction of the Blood Pressure in People With Resistant Hypertension

Study of the Prevalence of Endogenous Hypercortisolism in Patients With Resistant Hypertension (MOMENTUM)

An Efficacy, Safety, Tolerability and Dose Finding Study of XXB750 in Resistant Hypertension Patients.